Use
of Lyumjev in Patients With COVID-19
COVID-19
is an infectious respiratory disease caused by new variations of
the virus SARS-CoV-2, previously referred to as "2019
novel coronavirus."1,2
Lilly
has not studied the use of Lyumjev in patients with COVID-19 nor in
patients at risk of contracting COVID-19.
Clinicians
should use their clinical judgment in determining the most
appropriate approach in treating a patient with Lyumjev who has been
exposed to or has confirmed or suspected COVID-19.
Infectious
Disease Resources for COVID-19
For
current information on COVID-19, please refer to
References
1.
Naming the coronavirus disease (COVID-19) and the virus that causes
it. World Health Organization. Accessed March 18, 2020.
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it
2.
Tang X, Wu C, Li X, et al. On the origin and continuing evolution of
SARS-CoV-2. Natl Sci Rev. Published online March 3, 2020.
https://doi.org/10.1093/nsr/nwaa036
3.
Coronavirus disease (COVID-19) outbreak. World Health Organization
Europe. Accessed March 20, 2020.
http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/novel-coronavirus-2019-ncov
4.
International Diabetes Federation Europe. COVID-19 outbreak:
guidance for people with diabetes.
https://www.idf.org/our-network/regions-members/europe/europe-news/196-information-on-corona-virus-disease-2019-covid-19-outbreak-and-guidance-for-people-with-diabetes.html.
Accessed March 18, 2020
5.
COVID-19. European Centre for Disease Prevention and Control.
Accessed March 20, 2020.
https://www.ecdc.europa.eu/en/novel-coronavirus-china
Glossary
COVID-19
= coronavirus disease 2019
Lilly
= Eli Lilly and Company
SARS-CoV-2
= severe acute respiratory syndrome coronavirus 2
URLi
= ultra rapid lispro
EU
WHO = World Health Organization (European regional office)
IDF
= International Diabetes Federation
ECDC
= European Centre for Disease Prevention and Control
▼ This
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.